ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintSite TitleTitle ChevronIcon Twitter
Pharmaceuticals

India halts China-made antibody tests after suspect results

Two-day pause comes as South Korean firm starts local production of kits

Workers wearing protective gear handle medicines at medicine shop in Kolkata, India.   © Reuters

NEW DELHI -- India's top medical research body has asked the country's states to stop using Chinese-made coronavirus antibody tests for two days following reports of doubtful reliability.

Chinese manufacturers Guangzhou Wondfo Biotech and Zhuhai Livzon Diagnostics supplied these testing kits and are now being investigated by the Indian Council of Medical Research, according to media reports.

The move comes as the Indian subsidiary of South Korean firm SD Biosensor starts production of antibody test kits at its plant in the northern state of Haryana, with a capacity to manufacture 500,000 per week.

India's complaint follows reports of other countries, including Spain and Turkey, rejecting Chinese-supplied testing kits and other medical supplies exported as part of Beijing's effort to fight the coronavirus pandemic.

India recently imported about 700,000 of these kits from China and distributed them to various parts of the country with the aim of speeding up detection of coronavirus cases. Antibody tests of blood samples, which detect signs of the body's response to the virus rather than the virus itself, yield results faster than tests that rely on throat swabs.

Wondfo Biotech provided about 500,000 kits to India, while Livzon Diagnostics supplied 200,000 kits, an unnamed ICMR official was quoted as saying by ANI news agency. Some of the kits have been found "faulty" by the council, the official said.

Ji Rong, the spokesperson for the Chinese Embassy in India, reacted on Twitter to reports about the rapid testing kits. "China attaches great importance to the quality of exported medical products," she said. "Will keep close communication with Indian concerned agency and provide necessary assistance."

On Tuesday, Wondfo Biotech issued a statement disputing reports in the U.K.'s Daily Mail and The New York Times that questioned the accuracy of the Chinese company's tests. The company called the claims in the reports "inaccurate" and said "antibody tests are used as a supplement to nucleic acid detection testing or virus culture identification methods to increase the likelihood of an accurate result."

Raman R. Gangakhedkar, head of the ICMR's epidemiology and communicable diseases division, separately told a media briefing that authorities in one state had complained about the detection rate of the Chinese-made test kits. 

The council contacted three more states and found "lot of variation in the test results of positive samples, ranging from 6% to 71%," Gangakhedkar said.

"This is not a good thing because when we see a huge variation, we need to investigate it further, despite the fact that it is the first generation of the test which comes in the crude form and shows variation," he said.

Emphasizing that the coronavirus disease COVID-19 is new and that all tests need to be refined, Gangakhedkar said states have been requested to immediately pause use of the rapid testing kits for two days until ICMR experts are able to evaluate their effectiveness through field visits.

Meanwhile, India is set to receive locally made rapid testing kits from South Korea's SD Biosensor.

"The first batch was already rolled out on April 19," according to a statement issued by the Indian embassy in Seoul on Wednesday.

The manufacturing of the kits in the Haryana facility of the firm is "an excellent example of India's 'Make In India for World' as the company plans to ramp up production to meet growing demand in India as well as other part of the world," the embassy added.

"The Korean company capitalizes on India's low cost, high quality resources and skilled & technical workforce to enhance its global market share and profits, thereby creating a win-win situation," it added.

As of Wednesday evening, India's confirmed coronavirus cases had jumped to 20,471 with 652 deaths. Since March 25, the country's 1.3 billion people are under the world's biggest lockdown, initially meant for three weeks but later extended until May 3, to control the spread of virus infections.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Try 1 month for $0.99

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends July 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media